- Report
- January 2024
- 150 Pages
Global
From €4658EUR$4,850USD£3,977GBP
- Report
- March 2024
- 193 Pages
Global
From €5234EUR$5,450USD£4,469GBP
- Report
- January 2024
- 336 Pages
Global
€4797EUR$4,995USD£4,095GBP
- Report
- March 2024
- 187 Pages
Global
From €3241EUR$3,374USD£2,766GBP
€3601EUR$3,749USD£3,074GBP
- Report
- January 2022
- 200 Pages
Global
From €7203EUR$7,500USD£6,149GBP
- Report
- January 2022
- 60 Pages
Global
From €3794EUR$3,950USD£3,239GBP
- Report
- January 2020
- 76 Pages
United States
From €6718EUR$6,995USD£5,735GBP
- Report
- January 2020
- 18 Pages
Global
From €3837EUR$3,995USD£3,276GBP
- Report
- January 2024
- 89 Pages
Global
From €3500EUR$3,904USD£3,093GBP
Dermatophytic Onychomycosis (DO) is a fungal infection of the nail caused by dermatophytes. It is the most common type of onychomycosis, accounting for up to 50% of all nail infections. Treatment of DO typically involves the use of antifungal drugs, such as terbinafine, itraconazole, and fluconazole. These drugs are typically administered orally or topically, depending on the severity of the infection.
Infectious Diseases Drugs are a class of drugs used to treat a wide range of infectious diseases, including DO. These drugs are typically prescribed by a physician and are available in both generic and brand-name formulations. Commonly prescribed Infectious Diseases Drugs include antibiotics, antivirals, antifungals, and antiparasitics.
Some companies in the Dermatophytic Onychomycosis Drug market include Pfizer, Merck, Novartis, and Johnson & Johnson. Show Less Read more